Preclinical pipeline overview / Help fund a movie about AMR!

Dear All: Two things today.

First, Ursula Theuretzbacher, Miloje Savic, Christine Ardal, and Kevin Outterson have published in Nature Reviews Drug Discovery a brief but instructive snapshot of the global preclinical antibacterial pipeline. This report nicely complements the recent WHO analysis of the clinical pipeline that concluded that “the world is running out of antibiotics.”

You’ll want to read the paper yourself (it’s brief and open access), so I’ll just summarize by saying that Ursula and colleagues have analyzed applications from Year 1 of the CARB-X initiative, found a good diversity of approaches, and observed that this shows an encouraging alignment with the WHO priority pathogen list. This is encouraging, but these preclinical programs have still a long way to go, will require a lot of support en route, and are of course high risk. Discovery is hard, so let’s keep our fingers crossed!

Second, would you like to help fund a movie about antibiotic resistance? Bill Mudge, Jean Mudge, and Bob Milley are co-producers at Recombinant Films LLC. They have been steadily pulling together a internationally targeted documentary entitled Beating SuperBugs: Can We Win? for a generally educated but uninitiated audience. The documentary will focus on four of the CDC’s top superbug threats: tuberculosis; MRSA; C. difficile; and CRE. 

Using funds from a 2015 Kickstarter campaign, the team are now within about $100k of completing the film for release. If you’d like to help them get to done, you can make a tax-deductible contribution through their 501(c)3, non-profit fiscal sponsor, Catticus Corporation, Berkeley, CA. I think that non-technical material of this type is really valuable and I’m sure they’d appreciate any amount you might send.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

CDC-FDA webinar: Developing drugs to prevent healthcare-associated infections (30 Aug 2022)

Dear All, A quick note today to call your attention to an upcoming webinar that will be of wide interest. Substantial new details have been added to the online agenda materials for the 30 August 2022 (virtual, 8.30a-5.00p ET) webinar sponsored by CDC and FDA entitled “Drug Development Considerations for the Prevention of Healthcare-Associated Infections.” This is very

US Senate and House / Call for Pull incentives in FY23 budget

Dear All, The US Government is now building its budget for FY23 (Federal Year 2023, really runs 1 Oct 22 to 30 Sep 23). We had proposals from the House for the Department of Health and Human Services (DHHS) budget in late June;  and the proposal from Senate was released on 28 Jul 2022. Each

WHO Vaccine pipeline review; CDC on impact of COVID on AMR

Dear All, WHO continues to crank out those pipeline reviews … now we have one for bacterial vaccines! Go here for the press release and here for the report. The report considers data from 2010 forward and (interestingly) provides data on both active and failed projects. The review identified 94 active preclinical candidates and 61

IDWeek 2022: New pipeline sessions seek presentation of therapeutics and diagnostics!

Dear All: I have learned that the program for IDWeek 2022 will have specific dedicated pipeline sessions for therapeutics and diagnostics. The online details are relatively scant, but my understanding is that the therapeutics of interest for these sessions include antibacterials, antifungals, and non-HIV, non-COVID antiviral agents. There do not appear to be any constraints

Scroll to Top